Advances in understanding the anxiety disorders: The cognitive-affective neuroscience of 'false alarms'

Annals of Clinical Psychiatry

Volumn 18, Issue 3, 2006, Pages 173-182

  Stein, Dan J ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anxiety disorders; False alarms; Neurochemistry; Neurogenetics

Indexed keywords

CITALOPRAM; CLONIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DESIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NALOXONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; DISEASE CLASSIFICATION; EVOLUTION; FALSE ALARM; GENETICS; HUMAN; MEDICAL LITERATURE; MOOD DISORDER; NERVE CELL NETWORK; NEUROCHEMISTRY; NEUROSCIENCE; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PSYCHOBIOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; STRESS;

AFFECT; ANXIETY DISORDERS; AROUSAL; BIOLOGICAL EVOLUTION; BRAIN; BRAIN MAPPING; COGNITION; EVOLUTION; HUMANS; NERVE NET;

EID: 33750037653     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230600801192     Document Type: Review

References (104)

1. Freud S: Inhibitions, symptoms, and anxiety. Standard Edition, 1926; 20:111-131
2. Kessler RC, McGonagle KC, Zhao S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
3. Dupont RL, Rice DP, Miller LS et al.: Economic costs of anxiety disorders. Anxiety 1996; 2:167-172
4. van der Linden, GJH, Stein DJ, van Balkom, AJLM: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15S2:15-24
5. Stein DJ, Zungu-Dirwayi N, van der Linden GJ, and Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database of Systematic Reviews 2000; 4:CD002795
6. Stein DJ: Cognitive-Affective Neuroscience of Mood and Anxiety Disorders. London: Martin Dunitz; 2003
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC: American Psychiatric Press; 1980
8. Spitzer RL and Wakefield, JC.: DSM-IV diagnostic criterion for clinical significance: Does it help solve the false positive problem? Am J Psychiatry 1999; 156:1856-1864
9. van Praag, HM: Inflationary tendencies in judging the yield of depression research. Neuropsychobiol 1998; 37:130-141
10. Davidson JRT, Hughes DL, George LK et al.: The epidemiology of social phobia: Findings from the Duke Epidemiologic Catchment Area study. Psychological Med 1993; 23:709-718
11. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein S, Berndt ER, Davidson JRT, Ballenger JC, and Fyer AJ: The economic burden of the anxiety disorders in the 1990s. J Clin Psychiatry 1999; 60:427-435
12. Murray CJL and Lopez AD: Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Vol I. Harvard: World Health Organization, 1996
13. Ormel J, Koeter MWJ, van den Brink W et al.: Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991; 48:700-706
14. Marks IM and Nesse RM: Fears and fitness: An evolutionary analysis of anxiety disorders. Ethology and Sociobiology 1994; 15:247-261
15. Stearns SC: Evolution in Health and Disease. Oxford: Oxford University Press; 1999
16. Trevathan WR, McKenna JJ, and Smith EO: Evolutionary Medicine. New York: Oxford University Press; 1999
17. Darwin C: The Expression of Emotion in Man and Animals. London: John Murray; 1872
18. Stein DJ and Bouwer C: A neuro-evolutionary approach to the anxiety disorders. J Anx Disord 1997; 11:409-429
19. Klein DF: False suffocation alarms, spontaneous panics, and related conditions: An integrative hypothesis. Arch Gen Psychiatry 1993; 50:306-317
20. Young GB, Chandarana PC, Blume WT, McLachlan RS, Munos DG, and Girvin JP: Mesial temporal lobe seizures presenting as anxiety disorders. J Neuropsych Clin Neurosci 1995; 7:352-357
21. Cendes F, Andermann F, Gloor P, Gambardella A, Lopes-Cendes I, Watson C et al: Relationship between atrophy of the amygdala and ictal fear in temporal lobe epilepsy. Brain 1994; 117:739-746
22. Davis M and Whalen, PJ: The amygdala: Vigilance and emotion. Mol Psychiatry 6, 13-34. 2001
23. Klüver H and Bucy PC: Preliminary analysis of functions of the temporal lobes in monkeys. Archives of Neurology and Psychiatry 1939; 42:979-1000
24. Vythilingam M, Anderson ER, Goddard A, Woods SW, Staib LH, Charney DS, and Bremner JD: Temporal lobe volume in panic disorder - a quantitative magnetic resonance imaging study. Psychiatry Res 2000, 75-82
25. Reiman EM, Fusselman MJ, Fox PT, and Raichle ME: Neuroanatomical correlates of anticipatory anxiety. Science 1989; 243: 1071-1074
26. Reiman EM, Raichle ME, Robins E, Fusselman MJ, Fox PT, Price JL, and Hackman KA: Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 1989; 46: 493-500
27. Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P, and Perlmutter J: The application of positron emission tomography to the study of panic disorder. Am. J. Psychiatry 1986; 143:469-477
28. Gorman JM, Kent JM, Sullivan GM, and Coplan JD: Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry 2000; 157:493-505
29. Coplan JD, Gorman JM, and Klein DF: Serotonin related functions in panic-anxiety: A critical overview. Neuropsychopharmacol 1992; 6:189-200
30. Meyer JH, Swinson R, Kennedy SH, Houle S, and Brown GM: Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. Psychiatry Res 2000; 98:133-143
31. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Hersecovitz P, Charney DS, and Drevets WC: Reduced serotonin type 1A receptor binding in panic disorder. 2005
32. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. Int Clin Psychopharmacol 1995; 10:45-49
33. Bell C, Forshall S, Adrover M et al.: Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 2002; 16:5-14
34. Yehuda R and McFarlane AC: Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis. Am J Psychiatry 1995; 152:1705-1713
35. Macmillian TM: Post-traumatic stress disorder and severe head injury. Br J Psychiatry 1991; 159:431-433
36. Brewin CR: A cognitive neuroscience account of posttraumatic stress disorder and its treatment. Behav Res Ther 2001; 39: 373-393
37. Yehuda R: Risk Factors for Posttraumatic Stress Disorder. Washington, DC: American Psychiatric Press; 1999
38. Le Doux J: Fear and the brain: Where have we been, and where are we going? Biol Psychiatry 1998; 44:1229-1238
39. Hugdahl K: Cortical control of human classical conditioning: Autonomic and PET data. Pyschophysiology 1998; 35:170-178
40. Davidson RJ, Putnam KM, and Larson CL: Dysfunction in the neural circuitry of emotion regulation-a possible prelude to violence. Science 2001; 289:591-594
41. Maier S F: Exposure to the stressor environment prevents the temporal dissipation of behavioral depression/learned helplessness. Biol Psychiatry 2001; 49:763-773
42. Sanchez MM, Ladd CO, and Plotsky PM: Early adverse experience as a developmental risk factor for later psychopathology: Evidence from rodent and primate models. Dev Psychopathol 2001; 13:419-449
43. Rauch SL, Shin LM, Whalen PJ, and Pitman RK: Neuroimaging and the neuroanatomy of posttraumatic stress disorder. CNS Spectrums 1998; 3:31-41
44. Bonne O, Brandes D, Gilboa A, Gomori JM, Shenton ME, Pitman RK, and Shalev AY: Longitudinal MRI sudy of hippocampal volume in trauam survivors with PTSD. Am J Psychiatry 2001; 158: 1248-1251
45. Lyons DM, Yang C, Sawyer-Glover AM et al.: Early life stress and inherited variation in monkey hippocampal volumes. Arch Gen Psychiatry 2001; 58:1145-1151
46. Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR, Fischman AJ, Jenike MA, and Pitman RK: A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 1996; 53:380-387
47. Coplan JD and Lydiard RB: Brain circuits in panic disorder. Biol Psychiatry 1998; 44:1264-1276
48. Connor KM and Davidson JRT: The role of serotonin in posttraumatic stress disorder: Neurobiology and pharmacotherapy. CNS Spectrums 1998; 3S2:43-51
49. Penava SJ, Otto MW, Pollack MH, and Rosenbaum JF: Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anx 1996; 4:240-242
50. Seedat S, Warwick J, van Heerden B, Wessels C, Zungu-Dirwayi N, van Kradenburg J, and Stein DJ: Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2003
51. Arnsten AFT and Goldman-Rakic PS: Noise stress impairs prefrontal cortical cognitive function in monkeys: Evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry 1998; 55: 362-368
52. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, and Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45:1226-1229
53. Southwick SM and Yehuda R: The interaction between pharmacotherapy and psychotherapy in the treatment of posttraumatic stress disorder. Am J Psychotherapy 1993; 47:404-411
54. Robins LN, Holzer JE, Weissman MM et al.: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949-958
55. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu H-G, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, Wittchen H-U, and Yeh E-K: The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1994; 55S:5-10
56. Hollander E, Stein DJ, Broatch J, Himelein C, and Rowland C: A pharmacoeconomic and quality of life study of obsessive-compulsive disorder. CNS Spectrums 1997; 2:16-25
57. Rauch SL, Savage CR, Alpert NM et al: Probing striatal function in obsessive compulsive disorder: A PET study of implicit sequence learning. J Neurosci 1997; 9:568-573
58. Rapoport JL, Ryland DH, and Kriete M: Drug treatment of canine acral lick. Arch Gen Psychiatry 1992; 48:517-521
59. Stein DJ, Shoulberg N, Helton K, and Hollander E: The neuroethological model of obsessive-compulsive disorder. Compr Psychiatry 1992; 33:274-281
60. Stein DJ, O'Sullivan R, and Hollander E: Neurobiology of trichotillomania. Washington, DC: American Psychiatric Press; 1999
61. Stein DJ, Seedat S, and Potocnik F: Hoarding: A review. Israel J Psychiatry 1999; 36:35-46
62. Stein DJ, Liu Y, Shapira NA, and Goodman WK: The psychobiology of obsessive-compulsive disorder: How important is the role of disgust? Current Psychiatry Reports 2001; 3:281-287
63. Graybiel AM: The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem 1998; 70:119-136
64. Swedo SE, Leonard HL, Garvey M et al.: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264-271
65. Stein DJ, Goodman WK, Rauch SL: The cognitive-affective neuroscience of obsessive-compulsive disorder. Current Psychiatry Reports 2000; 2:341-346
66. Thoren P, Asberg M, and Bertilsson, L: Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980; 37:1289-1294
67. Zohar J, Insel TR, and Zohar-Kadouch RC: Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45:167-172
68. El Mansari M, Bouchard C, and Blier P: Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Neuropsychopharm 1995; 13: 117-127
69. Stein DJ, van Heerden B, Wessels CJ, van Kradenburg J, Warwick J, Wasserman HJ: Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1999; 23:1079-1099
70. Mundo E, Richter MA, Sam F, Macciardi F, and Kennedy J L: Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry 2000; 157: 1160-1161
71. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, and Charney D S: Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 2005; 47:577-585
72. Baxter LR, Schwartz JM, Bergman KS et al.: Caudate glucose metabolic rate changes with both drug and behavior therapy for OCD. Arch Gen Psychiatry 1992; 49:681-689
73. McDougle CJ, Epperson CN, Pelton GH et al.: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57:794-802
74. Weissman MM, Bland RC, Canino GJ, Greenwald S, Lee C-K, Newman SC, Rubio-Stipec M, and Wickramaratne PJ: The cross-national epidemiology of social phobia: a preliminary report. Int Clin Psychopharmacol 1996; 11S:9-14
75. De Waal F: Peacemaking among Primates. Cambridge, MA: Harvard University Press; 1989
76. Leary MR, Cutlip WD II, Brit TW, and Templeton JL: Social blushing. Psychological Bull 1992; 3:446-460
77. Bellugi U, Adolphs R, Cassady C et al.: Towards the neural basis for hypersociability in a genetic syndrome. Neuroreport 1999; 10: 1653-1657
78. Reiss AL, Eckert MA, Rose FE, Karchemskiy A, Kesler S, Chang M, Reynolds MF, Kwon H, and Galaburda A: An experiment of nature: brain anatomy parallels cognition and behavior in Williams syndrome. J Neurosci 2004; 24:5009-5015
79. Mobbs D, Garrett AS, Menon V, Rose FE, Bellugi U, and Reiss AL: Anomalous brain activation during face and gaze processing in Williams syndrome. Neurology 2004; 62:2070-2076
80. Allison T, Puce A, and McCarthy G: Social perception from visual cues: Role of the STS region. Trends in Cognitive Sciences 2000; 4:267-277
81. Adolphs R: The neurobiology of social cognition. Current Opinion in Neurobiology 2001: 231-239
82. Birbaumer N, Grodd W, Diedrich O et al.: fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 1998; 9:1223-1226
83. Tillfors M, Furmack T, Marteinsdottir I et al.: Cerebral blood flow in subjects with social phobia during stressful speaking tasks: A PET study. Am J Psychiatry 2001; 158:1220-1226
84. Schneider F, Weiss U, Kessler C et al.: Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry 1999; 45:863-871
85. Potts NL, Davidson JR, Krishnan KR et al.: Magnetic resonance imaging in social phobia. Psychiatry Res 1994; 52:35-42
86. Davidson JRT, Boyko O, Charles HC et al.: Magnetic resonance spectroscopy in social phobia. J Clin Psychiatry 1993; 54S:19-25
87. Tupler LA, Davidson JRT, Smith RD et al.: A repeat proton magnetic resonance spectroscopy study in social phobia. Biol Psychiatry 1997; 42:419-424
88. Nutt DJ, Bell CJ, and Malizia AL: Brain mechanisms of social anxiety disorder. J Clin Psychiatry 1998; 59:4-11
89. McDonald AW, III, Cohen JD, Stenger VA et al.: Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000; 288:1835-1838
90. Rauch SL, Savage CR, Alpert NM et al.: The functional neuroanatomy of anxiety: A study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry 1997; 42:446-452
91. Raleigh MJ, Brammer GL, and McGuire MT: Male dominance, serotonergic systems, and the behavioral and physiological effects of drugs in vervet monkeys (Cercopithecus aethiops sabaeus). In: Miczek, KA, ed. Ethopharmacology: Primate Models of Neurospychiatric Disorders. New York: Alan R Liss: 1983
92. Grant KA, Shively CA, Nader MA et al.: Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 1998; 29:80-83
93. Stein DJ, Westenberg H, and Liebowitz MR: Social anxiety disorder and generalized anxiety disorder: Serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 2002; 63S6:12-19
94. Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Langstrom B, Oreland L, and Fredrikson M: Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 2004; 362:189-192
95. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, and Leinonen, E: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997; 154:239-242
96. Schneier FR, Liebowitz MR, and Abi-Dargham A: Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry 2001; 157:457-459
97. Stein DJ, Ipser JC, and Balkom AJ: Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004; 4:CD001206
98. Schwartz CE, Wright CI, Shin LM, Kagan J, and Rauch SL: Inhibited and uninhibited infants "grown up": Adult amygdalar response to novelty. Science 2003; 5627:1952-1953
99. Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM, Kagan J, Snidman N, Faraone SV, Hirshfeld-Becker, D, Tsuang MT, Slaugenhaupt SA, Rosenbaum JF, and Sklar PB. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 2005; 57:1485-1492
100. Montgomery SA: Obsessive compulsive disorder is not an anxiety disorder. Int Clin Psychopharmacol 1993; S8:57-62
101. Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, Seedat S, and Stein DJ: Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004; 14:30
102. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, and Baxter LR Jr.: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998; 84:1-6
103. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, and Fredrikson M: Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psych 2002; 59:425-433
104. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand F, Hodges L, and Davis M: Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psych 2004; 61:1136-1144